Paradoxical exacerbation of tuberculosis after TNFα antagonist discontinuation: Beware of immune reconstitution inflammatory syndrome

Joint Bone Spine

Volumn 78, Issue 3, 2011, Pages 312-315

  Rivoisy, Claire ^a   Amrouche, Lucile ^a   Carcelain, Guislaine ^b   Séréni, Daniel ^a   Bourgarit, Anne ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Immune reconstitution inflammatory syndrome; Paradoxical deterioration; TNF antagonists; Tuberculosis

Indexed keywords

ADALIMUMAB; ANTIINFECTIVE AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; PYRAZINAMIDE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACTINOMYCETALES INFECTION; AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DRUG WITHDRAWAL; ENTERITIS; FEMALE; GIANT CELL ARTERITIS; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; LIVER ABSCESS; LIVER BIOPSY; LUNG LAVAGE; LYMPHADENOPATHY; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; RHEUMATOID ARTHRITIS; TUBERCULIN TEST; UNSPECIFIED SIDE EFFECT;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTITUBERCULAR AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 79955526333     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.01.003     Document Type: Article

References (14)

1. Benda R., David M., Franchel F., et al. Multiple brain cold abscesses during pulmonary tuberculosis treated by antibiotics; proof of their tuberculosis origin furnished by the surgical specimens. Bull Mem Soc Med Hop Paris 1954, 70:802-806.
2. Meintjes G., Lawn S.D., Scano F., et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523.
3. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumour necrosis factor α-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
4. Bray M.G., Poulain C., Dougados M., et al. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumour necrosis factor blocker treatment. Joint Bone Spine 2010, 77:135-141.
5. Bourgarit A., Carcelain G., Martinez V., et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006, 20:F1-F7.
6. Cheng V.C., Yam W.C., Woo P.C., et al. Risk factors for developpement of paradoxical response during antituberculous therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis 2003, 22:597-602.
7. Muller M., Wandel S., Colebunders R., et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:251-261.
8. Arend S.M., Leyten E.M.L., Franken W.P.J., et al. A patient with de novo tuberculosis during anti-tumour necrotizing factor-α therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007, 45:1470-1475.
9. Garcia Vidal C., Rodriguez Fernandez S., Martinez Lacasa J., et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005, 40:756-759.
10. Youn Y.K., Kim J.Y., Sohn J.W., et al. Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case report. J Med Case Rep 2009, 3:66-73.
11. Belknap R., Reves R., Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Correspondence. Int J Tuberc Lung Dis 2005, 9:1057-1060.
12. Szerszen A., Gupta S., Seminara D., et al. Peritoneal tuberculosis complicated by immune reconstitution inflammatory syndrome in a patient treated with infliximab?: a case for adjuvant immunosuppressive therapy. J Clin Rheumatol 2009, 15:417-418.
13. Wallis R.S., van Vuuren C., Potgieter S. Adalimumb treatment of life-threatening tuberculosis. Clin Infect Dis 2009, 48:1429-1432.
14. Wallis R.S. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005, 41:201-208.